drugset
drugset / Trial / NCT05979818

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

NCT05979818 ↗

Phase 1 Recruiting 6 enrolled Second Xiangya Hospital of Central South University Innovent Biologics (Suzhou) Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.

Timeline

Start
2024-11-13
Primary completion
2025-08-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 10 mg Oral
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Paclitaxel Small molecule 100 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Paclitaxel Small molecule 260 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous
Background Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

non-small cell lung carcinoma